Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 10-arm NCT04663347

Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL) (EPCORE™ NHL-2)

A Phase 1b/2, Open-Label Trial to Assess the Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Combination With Other Agents in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Sponsor: AbbVie

Conditions Diffuse Large B-Cell Lymphoma Follicular Lymphoma

Interventions Epcoritamab Lenalidomide Rituximab and Lenalidomide gemcitabine and oxaliplatin rituximab and bendamustine rituximab and lenalidomide rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin rituximab, ifosfamide, carboplatin, and etoposide phosphate

Updated 34 times since 2021 Last updated: Mar 2, 2026 Started: Nov 3, 2020 Primary completion: Sep 30, 2027 Completion: Sep 30, 2027

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1/PHASE2 trial investigates Diffuse Large B-Cell Lymphoma and Follicular Lymphoma and is currently ongoing. AbbVie leads this study, which shows 34 recorded versions since 2020 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

34 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Feb 2026 — Mar 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jan 2026 — Feb 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2
Dec 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE1/PHASE2
Nov 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

▶ Show 29 earlier versions

Oct 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2025 — Oct 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Aug 2025 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jun 2025 — Aug 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
May 2025 — Jun 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Apr 2025 — May 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Mar 2025 — Apr 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Feb 2025 — Mar 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jan 2025 — Feb 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2

Status: Recruiting → Active Not Recruiting
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE1/PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE1/PHASE2
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
May 2024 — Jun 2024 [monthly]

Recruiting PHASE1_PHASE2
Apr 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1_PHASE2
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE1_PHASE2
Sep 2023 — Feb 2024 [monthly]

Recruiting PHASE1_PHASE2
Jun 2023 — Sep 2023 [monthly]

Recruiting PHASE1_PHASE2
Mar 2023 — Jun 2023 [monthly]

Recruiting PHASE1_PHASE2
Jan 2023 — Mar 2023 [monthly]

Recruiting PHASE1_PHASE2
May 2022 — Jan 2023 [monthly]

Recruiting PHASE1_PHASE2
Dec 2021 — May 2022 [monthly]

Recruiting PHASE1_PHASE2
Oct 2021 — Dec 2021 [monthly]

Recruiting PHASE1_PHASE2
Sep 2021 — Oct 2021 [monthly]

Recruiting PHASE1_PHASE2
Jan 2021 — Sep 2021 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Nov 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AbbVie
Genmab

Data source: Genmab

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aarhus, Denmark , Amsterdam, Netherlands , Ann Arbor, United States , Barcelona, Spain , Bergamo, Italy , Birmingham, United States , Bologna, Italy , Borås, Sweden , Boston, United States , Bruges, Belgium and 42 more locations